KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.98

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.

Jeanne Tie, Yuxuan Wang, Jonathan M Loree, Joshua D Cohen, Rachel Wong, Timothy Price, Niall C Tebbutt, Val Gebski, David Espinoza, Matthew Burge, Sam Harris, James Lynam, Belinda Lee, Margaret M Lee, Daniel Breadner, Marlyse Debrincat, Siavash Foroughi, Lorraine Chantrill, Stephanie H Lim, Sharlene Gill, Chris O'Callaghan, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Chetan Bettegowda, Nicholas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Peter Gibbs, AGITG DYNAMIC-III Study Group (Intergroup Study of the Australasian Gastro-Intestinal Trials Group and Canadian Cancer Trials Group)

Nat Med 31(12) 4291-4300

PMID41115959
PMCID-
DOI10.1038/s41591-025-04030-w
发表日期2025-10-20
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:This is a phase 2/3 trial, not exclusively Phase III. The publication types list both 'Clinical Trial, Phase III' and 'Clinical Trial, Phase II', indicating a combined phase design.
摘要

摘要

Adjuvant chemotherapy in stage III colon cancer provides uncertain benefit at the individual level. Circulating tumor DNA (ctDNA) may help refine risk-adjusted treatment selection. In this multicenter, randomized, phase 2/3 trial, patients with stage III colon cancer underwent ctDNA testing 5-6 weeks after surgery and were assigned (1:1) to ctDNA-guided or standard management. In the ctDNA-guided arm, patients negative for ctDNA received de-escalated therapy, whereas ctDNA-positive patients received escalated therapy. Clinicians prespecified the standard regimen. Primary endpoints were 3-year recurrence-free survival (RFS) for ctDNA-negative patients and 2-year RFS for ctDNA-positive patients. Secondary endpoints included treatment-related hospitalization and ctDNA clearance. Among 968 evaluable patients, 702 (72.5%) were ctDNA negative. With a median follow-up of 47 months, ctDNA-negative patients experienced significantly fewer recurrences than ctDNA-positive patients (3-year RFS 87% versus 49%; P < 0.001). In ctDNA-negative patients, de-escalation reduced oxaliplatin use (34.8% versus 88.6%) and hospitalizations (8.5% versus 13.2%) but yielded slightly lower RFS than standard management (85.3% versus 88.1%), not meeting the non-inferiority margin. In ctDNA-positive patients, higher ctDNA burden correlated with recurrence risk (3-year RFS 77% to 23% across quartiles; P < 0.001). Escalated therapy did not improve outcomes over standard management (2-year RFS 51% versus 61%). There was no unexpected toxicity. Persistent ctDNA after treatment predicted markedly worse prognosis (3-year RFS 14% versus 79%). ctDNA is validated as a strong prognostic classifier. ctDNA-guided de-escalation reduced oxaliplatin exposure and adverse events with outcomes approaching standard of care, whereas exploratory chemotherapy intensification conferred no RFS benefit, suggesting a need for novel strategies in ctDNA-positive disease.Australian New Zealand Clinical Trials Registry Identifier: ACTRN12617001566325 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。